Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company focused on central nervous system (CNS) and immunology treatments, announced that its management team will participate in two upcoming investor conferences in May 2026. The company will present at the RBC Capital Markets Global Healthcare Conference on May 19 in New York and at A.G.P.'s Annual Virtual Healthcare Conference on May 20. These appearances signal Tonix's commitment to engaging with the investment community and updating stakeholders on its recent achievements and pipeline developments.
The conferences come on the heels of the FDA approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the company’s flagship medicine and the first new treatment for fibromyalgia in over 15 years. TONMYA represents a significant milestone for Tonix, which has built a CNS commercial infrastructure to support its marketed products, including the acute migraine treatments Zembrace SymTouch and Tosymra. The company is also exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, expanding its therapeutic reach beyond fibromyalgia.
In addition to its CNS portfolio, Tonix is advancing a pipeline of immunology programs. Notable candidates include TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor designed to prevent kidney transplant rejection. The company’s pipeline also features TNX-2900, a Phase 2-ready treatment for Prader-Willi syndrome, a rare genetic disorder. These programs underscore Tonix’s focus on areas of high unmet medical need, with the potential to address significant gaps in current treatment options.
Participation in these investor conferences provides Tonix with a platform to highlight its commercial progress and pipeline milestones. The RBC Capital Markets Global Healthcare Conference is a prominent event attracting institutional investors and industry analysts, while A.G.P.’s virtual conference offers broader accessibility. Investors and interested parties can access additional information about Tonix through the company’s newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/ZZpG2.
Tonix Pharmaceuticals is a fully integrated commercial-stage biotechnology company dedicated to developing treatments for CNS and immunology conditions. With a recently approved product and a robust pipeline, the company is positioned to address critical unmet needs in fibromyalgia, migraine, depression, stress disorders, rare diseases, and transplant rejection. The upcoming conference presentations will likely provide further insights into the company’s strategic direction and growth prospects.
